Hutchison Chi-Med plans to file two New Drug applications for innovative cancer drugs in 2016, said Christian Hogg, CEO of the company, in an upbeat year-end earnings report. The company expects results from a Phase II trial of fruquintinib as a treatment for colorectal cancer soon, which will trigger a milestone payment from Lilly. It also expects milestones from savolitinib, a treatment for kidney and gastric cancer that is out-licensed to AstraZeneca later in 2015. Chi-Med will file for China approval of fruquintinib and US approval of savolitinib.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
